Roche Holding AG Ordinary Shares new ROP

Morningstar Rating
CHF 398.00 −1.20 (0.30%)
View Full Chart

Company Report

Price vs Fair Value

ROP is trading at a LOCK|H!$^ premium.
Price
CHF 399.20
Fair Value
LOCK|K$
Uncertainty
LOCK|fF
1-Star Price
LOCK|$Q
5-Star Price
B$v
Economic Moat
LOCK|@m
Capital Allocation
LOCK|Wwy!?Fs<

Bulls Say, Bears Say

Bulls

Roche and its innovative US arm Genentech have a solid history of generating blockbuster therapies in oncology, and Roche's pipeline is full of novel candidates, with a particularly large late-stage pipeline.

Bears

Roche's immuno-oncology drug Tecentriq was launched third to market behind Bristol's Opdivo and Merck's Keytruda, raising questions about Roche's innovation.

News

Trading Information

Previous Close Price
CHF 399.20
Day Range
CHF 396.20–401.20
52-Week Range
CHF 291.00–410.90
Bid/Ask
CHF 397.80 / CHF 397.90
Shares Outstanding
796.77M
Market Cap
CHF 316.56B
Volume/Avg
640,241 / 990,706

Key Statistics

Price/Earnings (Normalized)
21.73
Price/Sales
5.10
Dividend Yield (Trailing)
2.45%
Dividend Yield (Forward)
2.45%
Dividend Payment Schedule
Mar
Total Yield
2.45%

Company Profile

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
112,774

Competitors

Valuation

Metric
ROP
REGN
ABBV
Price/Earnings (Normalized)
21.7318.6032.42
Price/Book Value
9.732.92—
Price/Sales
5.105.977.68
Price/Cash Flow
15.9817.2621.57
Price/Earnings
ROP
REGN
ABBV

Financial Strength

Metric
ROP
REGN
ABBV
Quick Ratio
0.802.720.56
Current Ratio
1.233.350.87
Interest Coverage
13.49106.895.20
Quick Ratio
ROP
REGN
ABBV

Profitability

Metric
ROP
REGN
ABBV
Return on Assets (Normalized)
15.81%14.40%16.61%
Return on Equity (Normalized)
48.77%18.83%—
Return on Invested Capital (Normalized)
23.90%15.64%36.97%
Return on Assets
ROP
REGN
ABBV

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
LOCK|gGfWc>#fLOCK|khC$1T
Johnson & Johnson
JNJ
LOCK|!<YkKX#LOCK|v#$$643B
AbbVie Inc
ABBV
LOCK|g>f?$xLOCK|<R$501B
Roche Holding AG ADR
RHHBY
LOCK|hpl^%>PLOCK|#h$378B
Merck & Co Inc
MRK
LOCK|QP<ld#LOCK|lB$327B
Novartis AG ADR
NVS
LOCK|@%%#@&gPLOCK|<Vd$285B
AstraZeneca PLC
AZN
LOCK|^^Kw^qxLOCK|hd$271B
Amgen Inc
AMGN
LOCK|@b#%Q?mNLOCK|Vcm$237B
Gilead Sciences Inc
GILD
LOCK|np%H!&LOCK|ykJ$207B
Novo Nordisk AS ADR
NVO
LOCK|^$&WjwLOCK|c>$172B

Sponsor Center